Moderna (NASDAQ:MRNA), founded in 2010 and headquartered in Cambridge, Massachusetts, is a biotechnology company pioneering the development of messenger RNA (mRNA) therapeutics and vaccines. Leveraging an innovative mRNA platform, the company designs and engineers mRNA molecules to instruct cells to produce proteins with therapeutic or preventative effects. This approach underpins Moderna’s mission to transform the treatment and prevention of disease through a new class of medicines.
The company gained global recognition with the authorization of its mRNA-based COVID-19 vaccine, commercially known as Spikevax, developed in collaboration with the U.S. National Institutes of Health. Beyond its flagship vaccine, Moderna maintains a diversified pipeline that includes vaccines for respiratory syncytial virus (RSV), cytomegalovirus (CMV), seasonal influenza and combination vaccines targeting multiple pathogens. In addition to infectious disease programs, Moderna is advancing personalized cancer vaccines, rare disease therapies and cardiovascular candidates, positioning mRNA technology at the core of its therapeutic strategy.
Moderna operates manufacturing facilities in North America and Europe, with plans to expand capacity in Asia and other regions to support global supply. Strategic partnerships with governments, academic institutions and biopharmaceutical companies have facilitated clinical development, regulatory approvals and distribution channels worldwide. The company collaborates with organizations such as the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization to improve vaccine access in low- and middle-income countries, underscoring its commitment to global health equity.
Under the leadership of Chief Executive Officer Stéphane Bancel, Moderna continues to refine its mRNA delivery platforms and manufacturing processes to enhance stability, efficacy and scalability. The executive team brings experience from the biotech and pharmaceutical industries, driving innovation across research, clinical development and commercial operations. With a robust intellectual property portfolio and a growing pipeline, Moderna aims to expand the applications of mRNA technology and address unmet medical needs worldwide.
